Loading…
Fredun Pharmaceuticals (BSE 539730)₹1,361+0.05%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Fredun Pharmaceuticals reported sales of ₹228 Cr, up 90.0% from Jun 2025, and net profit of ₹12.97 Cr, up 85.8% year on year. For the year to Mar 2026, sales were ₹636 Cr and net profit ₹32.90 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Sales | 167 | 120 | 145 | 161 | 213 | 228 |
| Expenses | 150 | 103 | 123 | 135 | 184 | 196 |
| Operating Profit | 16.98 | 16.97 | 21.98 | 25.96 | 28.96 | 32.94 |
| OPM % | 9.9% | 13.9% | 15.0% | 16.0% | 13.9% | 13.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 7.99 | 6.99 | 8.01 | 11.01 | 13.99 | 9.01 |
| Depreciation | 2.01 | 1.01 | 2.01 | 2.01 | 3.01 | 4.01 |
| Profit before tax | 7.01 | 9.01 | 13.01 | 14.01 | 11.01 | 21.02 |
| Tax % | 17.0% | 25.0% | 26.0% | 25.0% | 4.0% | 36.0% |
| Net Profit | 5.98 | 6.98 | 8.97 | 9.97 | 10.97 | 12.97 |
| EPS (Rs) | 4.24 | 4.76 | 6.65 | 6.52 | 6.58 | 7.97 |
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales | 455 | 636 | 748 |
| Expenses | 400 | 544 | 637 |
| Operating Profit | 51.95 | 90.88 | 110 |
| OPM % | 11.9% | 13.9% | 14.7% |
| Other Income | 1.99 | 3.99 | 0.00 |
| Interest | 21.98 | 38.97 | 42.02 |
| Depreciation | 5.01 | 8.01 | 11.04 |
| Profit before tax | 27.02 | 47.01 | 59.05 |
| Tax % | 28.0% | 31.0% | — |
| Net Profit | 19.93 | 32.90 | 42.88 |
| EPS (Rs) | 13.91 | 19.90 | 27.72 |
| Dividend payout % | 2.0% | 1.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 4.99 | 4.99 |
| Reserves | 137 | 272 |
| Borrowings | 168 | 223 |
| Other Liabilities | 179 | 143 |
| Total Liabilities | 488 | 643 |
| Fixed Assets | 52.93 | 118 |
| CWIP | 0.00 | 0.00 |
| Investments | 2.01 | 2.01 |
| Other Assets | 434 | 523 |
| Inventories | 240 | 270 |
| Trade receivables | 177 | 93.11 |
| Cash & equivalents | 5.01 | 65.09 |
| Total Assets | 488 | 643 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −17.01 | 12.01 |
| Cash from investing activity | −5.98 | −73.76 |
| Cash from financing activity | 26.88 | 121 |
| Net cash flow | 3.99 | 59.87 |
| Capex | 5.98 | 73.83 |
| Free cash flow | −23.02 | −62.01 |
| CFO / OP % | −32.1% | 13.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 142 | 53 |
| Inventory days | 267 | 219 |
| Days payable | 160 | 70 |
| Cash conversion cycle | 249 | 202 |
| Working capital days | 75 | 77 |
| ROCE % | — | 21.0% |
For the Jun 2026 quarter, Fredun Pharmaceuticals reported sales of ₹228 Cr, up 90.0% year on year and net profit of ₹12.97 Cr, up 85.8% year on year. The operating margin was 13.9%.
Fredun Pharmaceuticals' sales for the year to Mar 2026 were ₹636 Cr; over the last twelve months they were ₹748 Cr.
Net profit for the year to Mar 2026 was ₹32.90 Cr, and ₹42.88 Cr over the last twelve months. Earnings per share over the same trailing period were ₹27.72.
Fredun Pharmaceuticals reported borrowings of ₹223 Cr at Mar 2026, against cash and equivalents of ₹65.09 Cr.
Cash from operations was ₹12.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹62.01 Cr.